Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The Federal Joint Committee (G-BA) has prepared the path for a trial of the transcorneal electrical stimulation for retinitis pigmentosa in Germany

Retinitis Pigmentosa (RP) is a progressive degeneration of photoreceptor cells in the retina leading to severe vision impairment and, in most cases, to blindness. Transcorneal electrical stimulation (TES) uses electrical stimulation of the retina by a corneal electrode with the aim to slow down the destruction of the sensory cells and thereby preserving the visual performance of the patients for a longer time.

The Federal Joint Committee (G-BA) sees a potential in TES as a treatment alternative for patients with retinitis pigmentosa. However, the evidence is currently insufficient to show a benefit of the method. G-BA has therefore approved the conduction of a trial study according to §137e of the Social Code Book V. This paragraph regulates the generation of evidence of potential treatment methods troughs the co-funded trial to provide a decision base for inclusion into the statutory health benefit catalogue.

The trial procedure was initiated by a successful application submitted by the manufacturer (Okuvision). On July 20th 2017, the G-BA decided on a guideline defining the key points of the planned trial. The study will be designed as a double-blinded randomized controlled trial with placebo treatment as a control group. Data collection will take place in multiple centers in Germany. The primary endpoint measured in the study is a clinically relevant change of the range of vision; secondary endpoints are visual acuity, color perception, contrast perception, health-related quality of life and undesirable events.

The study will be conducted and evaluated by an independent research institute chosen through a public invitation to tender. The manufacturer will contribute to the costs for the conduction and evaluation of the trial. Once results from the trial are available, the G-BA will evaluate the evidence and decide about the inclusion of TES into the health benefits catalogue. In case of a positive decision, the method is categorized as reimbursable both for in- and out-patient settings.  

The full guideline of the trial in German is available here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.